Merck & Co Inc
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
Nurphoto | Nurphoto | Getty Images Pfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. Pfizer pitched its […]
Read More
Viking stock doubled Tuesday. In this article's the place the following moves in the weight problems room could arrive from
Anti-weight problems drugmakers Novo Nordisk and Eli Lilly have a big lead on their competitiveness, but supplied the large and beneficial marketplace, rivals are nevertheless keen to sign up for the race. Bank of America analyst Geoff Meacham has been quite bullish about the option, which he phone calls “unparalleled” offered the prevalence of obesity […]
Read More
New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
Blood sample of patient positive tested for sickle cell. Kitsawet Saethao | Istock | Getty Images The approval of two gene therapies to treat sickle cell disease has given hope to patients who suffer from the debilitating disease, which overwhelmingly affects Black people and people of color. Health officials now face a challenge in finding […]
Read More
Moderna posts surprise quarterly profit even as Covid vaccines sales plummet
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge […]
Read More
Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday tossed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations, which challenged […]
Read More
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024. Bill Clark | Cq-roll Call, Inc. | Getty Images Senators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on […]
Read More
Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024. Brendan McDermid | Reuters Here’s how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023. Despite ongoing macroeconomic concerns that have […]
Read More
Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
The logo for Merck & Co. is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021. Andrew Kelly | Reuters Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda […]
Read More
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks […]
Read More
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a […]
Read More